Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

US Patent 9758520 · Granted Sep 12, 2017

Estimated economic value: $14,166,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Isoxazolidines as RIPK1 inhibitors and use thereof2024
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020
Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists2020
Compounds as peptidic GLP1/glucagon/GIP receptor agonists2019
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity,2019
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity,2019
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity,2019
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity,2019
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity,2019
Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity,2019